Accueil   Diary - News   All news ERYTECH presents new data

ERYTECH presents new data

 

ERYTECH present new data on Graspa's mechanism of action at Ash Annual Meeting

 

ERYTECH Pharma, the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the presentation of promising preliminary data for the Company's lead product candidate, eryaspase, also known as ERY-ASP or under the trade name GRASPA®, at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 3-6, 2016 in San Diego, California.


Read the press release